<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cancer pain management with opioids: Optimizing analgesia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cancer pain management with opioids: Optimizing analgesia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cancer pain management with opioids: Optimizing analgesia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell K Portenoy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Zankhana Mehta, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ebtesam Ahmed, PharmD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet Abrahm, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Opioids are widely used for treatment of cancer-related pain because of their safety, multiple routes of administration, ease of titration, reliability, and effectiveness for all types of pain (ie, somatic, visceral, neuropathic). Although neuropathic pain may be more difficult to treat, a favorable response to opioid-based analgesia is often possible. (See  <a class="medical medical_review" href="/d/html/2795.html" rel="external">"Assessment of cancer pain", section on 'Inferred pathophysiology and treatment implications'</a>.)</p><p>Opioids are also drugs that can be misused. The public health consequences of opioid misuse drive the imperative that all clinicians assume responsibility for risk management when these drugs are prescribed for legitimate medical purposes. These issues are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids", section on 'Risk assessment and management for patients receiving opioids'</a>.)</p><p>This topic review will cover the use of opioids for cancer-related pain, with an emphasis on optimizing analgesia and minimizing side effects. Assessment of cancer pain, a review of specific cancer pain syndromes, general principles of cancer pain management, an overview of risk management in patients treated with opioids, prevention and management of opioid side effects, the clinical use of non-opioid analgesics (including nonsteroidal anti-inflammatory drugs [NSAIDs] and adjuvant analgesics), nonpharmacologic methods of cancer pain management, management of acute pain (eg, from a new injury or surgical procedure) in the patient chronically using opioids, and issues surrounding pain management in the last weeks of life are covered elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2795.html" rel="external">"Assessment of cancer pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2804.html" rel="external">"Overview of cancer pain syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2798.html" rel="external">"Cancer pain management: Use of acetaminophen and nonsteroidal anti-inflammatory drugs"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14249.html" rel="external">"Rehabilitative and integrative therapies for pain in patients with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14248.html" rel="external">"Interventional therapies for chronic pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14241.html" rel="external">"Palliative care: The last hours and days of life", section on 'Pain'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">OPIOID DRUGS USED IN CANCER PAIN MANAGEMENT</span></p><p class="headingAnchor" id="H3"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>Opioids act by binding to specific receptors, the best characterized of which are the mu, kappa, and delta receptors. These receptors are present in tissues throughout the body, including both the peripheral and central nervous systems.</p><p>Based upon their effects on the mu receptor, opioids are conventionally divided into pure mu receptor agonists, agonist-antagonists (of which there are two subtypes: partial agonists and mixed agonist-antagonists), and pure mu receptor antagonists  (<a class="graphic graphic_table graphicRef69457" href="/d/graphic/69457.html" rel="external">table 1</a>). Mu receptor antagonists have no intrinsic analgesic properties; they are used to prevent or reverse opioid effects. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Opioid bowel dysfunction'</a>.)</p><p>With few exceptions, the management of chronic cancer pain usually involves the long-term administration of pure mu receptor agonists. However, several of the agonist-antagonist drugs are commercially available in the United States and other countries, and at least one, <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, is used for treatment of cancer-related pain in some settings. Several other centrally acting analgesics, including <a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">tramadol</a> and <a class="drug drug_general" data-topicid="9511" href="/d/drug information/9511.html" rel="external">tapentadol</a>, have some mu agonist effects mixed with other prominent mechanisms and also are used for cancer pain in some circumstances.</p><p class="headingAnchor" id="H10"><span class="h2">Pure mu agonists commonly used for cancer pain</span></p><p class="headingAnchor" id="H11"><span class="h3">Morphine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> is the prototype opioid drug for moderate to severe cancer pain on the third step of the WHO analgesic ladder  (<a class="graphic graphic_figure graphicRef63298" href="/d/graphic/63298.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/2795.html" rel="external">"Assessment of cancer pain", section on 'Pain characteristics'</a>.)</p><p>The WHO analgesic ladder is usually considered to be a standard for comparison. In the original WHO guidelines, this preference for <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> was not based upon any existing comparative data. Since then, randomized trials and systematic reviews have failed to demonstrate the superiority of morphine over any other mu agonist (such as <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a>, <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>, or <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>) in terms of efficacy or tolerability [<a href="#rid2">2-9</a>]. Furthermore, there is very large intraindividual variation in the response to the different mu agonist drugs and no way to predict whether a patient will have a more favorable balance between analgesia and side effects when given morphine or one of the other drugs, unless a previous response to a specific drug helps to guide the choice of agent [<a href="#rid2">2</a>].</p><p>Accordingly, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> should not be considered the "drug of choice," but rather, just one of many drugs that could be selected for chronic cancer pain. The decision to select one or another is often based upon the experience of the clinician, prior experience of the patient, cost, dosing implications of the formulation, and other factors, including renal and hepatic function. (See <a class="local">'Practical considerations in opioid use'</a> below.)</p><p><a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> has a short half-life, but it is available in multiple formulations, including immediate-release tablets and modified-release tablets and capsules with prolonged effects after a dose, oral liquid, suppository, and solution for intravenous (IV) and subcutaneous (SC) use, and also may be useful for breakthrough pain when coadministered with a long-acting formulation  (<a class="graphic graphic_table graphicRef111207" href="/d/graphic/111207.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/2795.html" rel="external">"Assessment of cancer pain", section on 'Acute versus chronic pain'</a>.)</p><p>Regardless of the formulation, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> is primarily metabolized in the liver and its metabolites are renally excreted. Two active metabolites have been extensively studied, morphine-3-glucuronide (M3G) and morphine-6-gluconoride (M6G) [<a href="#rid10">10</a>]. Preclinical data and limited human studies suggest that M6G contributes to analgesic activity and M3G may be the cause of some of the side effects that occur during morphine therapy, although this is not yet proven [<a href="#rid11">11-14</a>].</p><p>Metabolite concentration may be idiosyncratically high as a result of unknown but presumed genetic factors, or more commonly, metabolite concentration may increase relative to the parent compound (<a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>) as a result of renal disease that reduces excretion of both glucuronides. These metabolites are not routinely measured in clinical practice. If this occurs, use of the drug may be associated with unanticipated potency or side effects. Clinically, this means that morphine should be administered cautiously in the setting of renal insufficiency, and if fluctuation in kidney function can be anticipated, morphine may not be the preferred opioid given the risk of changes in effects and side effects as metabolite accumulation occurs. (See <a class="local">'Patients with kidney impairment'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h3">Oxycodone, hydrocodone, hydromorphone, and oxymorphone</span><span class="headingEndMark"> — </span>As with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">hydrocodone</a>, and <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a> all have short half-lives and all are available in multiple formulations. In the United States, all four of these drugs are also available in liquid form as well as long-acting, modified-release formulations.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxycodone</strong> – <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">Oxycodone</a> binds to both mu and kappa receptors. Clinical studies have not substantiated systematic differences in efficacy or tolerability compared with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> or other mu agonists [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydromorphone</strong> – Multiple dose forms are available for <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, including oral liquid, immediate release tablet, extended release tablet, suppository, and solution for IV or SC use. The extended release form of hydromorphone is available in 8, 12, and 16 mg strengths, and is dosed once daily. Caution must be used to avoid medication errors when prescribing this product, as 8 mg tablets are also available as immediate-release hydromorphone tablets.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">Hydromorphone</a> is highly soluble in water [<a href="#rid16">16</a>] and a commercially available concentrated solution (10 mg/mL) facilitates SC or IV administration of relatively high doses. Some clinicians prefer to use hydromorphone in patients with renal insufficiency because its active, renally cleared metabolites appear in relatively low concentration (compared with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>) and may be unlikely to cause unanticipated effects. (See <a class="local">'Patients with kidney impairment'</a> below.)</p><p></p><p class="bulletIndent1">However, the quality of the evidence of the benefits and harms of <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> compared with other opioids for cancer pain is very low [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxymorphone</strong> – The analgesic efficacy of <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a> appears to be comparable with other opioids [<a href="#rid18">18</a>]. It has a relatively low propensity to release histamine, a characteristic also shared with <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>. At least in theory, this may reduce the risk of pruritus or urticaria, although there is no evidence that this difference is clinically relevant. Oxymorphone is available in immediate-release tablets and a generic modified-release tablet. The proprietary long-acting formulation, Opana ER, was voluntarily withdrawn from the United States market in July 2017 at the request of the US Food and Drug Administration because of concerns that the benefits of the drug were outweighed by the risks related to continued injection abuse of the drug, despite a reformulation in 2012 intended to make the drug resistant to physical and chemical manipulation [<a href="#rid19">19,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydrocodone</strong> – Short-acting <a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">hydrocodone</a> is only available in the United States in combination with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>. The amount of the nonopioid constituent limits use of these short-acting combinations to relatively opioid-naïve patients with moderate or severe pain.</p><p></p><p class="bulletIndent1">Long-acting formulations of <a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">hydrocodone</a> (Zohydro ER and Hysingla ER) are available in the United States for the management of pain severe enough to require daily, around-the-clock, long-term analgesic treatment and for which alternative treatment options are inadequate. These formulations contain only hydrocodone and, like other single entity pure mu agonists, are classified as Schedule II controlled substances. Although the analgesic efficacy of long-acting hydrocodone has been shown in a placebo-controlled trial conducted in patients with chronic low back pain, the only data addressing efficacy in cancer populations are from observational studies [<a href="#rid21">21</a>]. Also like other oral, modified-release, long-acting opioid formulations, these drugs are formulated to deter abuse by crushing, chewing, or dissolving [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/113892.html" rel="external">"Abuse deterrent opioids"</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h3">Fentanyl</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">Fentanyl</a> is a highly lipophilic opioid that may be used parenterally or in formulations developed for transdermal or oral transmucosal delivery. The transdermal formulation is used for chronic pain. Both the non-oral route and the relatively infrequent dosing (every two to three days for transdermal fentanyl) are considered advantages by some patients. Although data from clinical trials about the potential for a relatively reduced risk of constipation from transdermal fentanyl are conflicting [<a href="#rid23">23-26</a>], three meta-analyses have found a significant advantage for transdermal fentanyl over sustained release oral <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> in terms of this side effect [<a href="#rid27">27-29</a>]. Transdermal fentanyl may be preferred over an orally administered opioid in the setting of poor gastrointestinal tract absorption or dysphagia, and for patients in whom constipation has been or is expected to be difficult to manage. Fentanyl may also be preferred over morphine in patients with kidney impairment due to lack of active metabolites. (See <a class="local">'Patients with kidney impairment'</a> below.)</p><p>Exposing the patch to heat (eg, an increase in body temperature, use of a heating pad or warming blanket during surgery) may cause an unintentional increase in systemic <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> absorption, which may increase the risk of respiratory depression. In addition, fentanyl patches contain metal, which can pose a risk for local skin burn during magnetic resonance imaging (MRI) [<a href="#rid30">30</a>]. Clinicians should advise patients to remove the patch before an MRI procedure and replace it after completion of the scan. (See  <a class="medical medical_review" href="/d/html/113084.html" rel="external">"Patient evaluation for metallic or electrical implants, devices, or foreign bodies before magnetic resonance imaging", section on 'Drug infusion pumps and patches'</a>.)</p><p>Decreased absorption may also be a concern in cachectic patients [<a href="#rid31">31</a>].</p><p>Rapid-onset transmucosal preparations of <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> are discussed below. (See <a class="local">'Management of breakthrough pain'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h3">Levorphanol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9556" href="/d/drug information/9556.html" rel="external">Levorphanol</a> is distinguished by its relatively long half-life (approximately 12 to 16 hours). Experience in the use of this drug is relatively limited in the US, but it should be viewed as another option for the treatment of cancer pain, particularly when other mu agonists have not been well tolerated or are unavailable.</p><p class="headingAnchor" id="H15"><span class="h3">Methadone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is a mu agonist opioid, but it has a unique pharmacology that presumably underlies both the observation that some patients experience a surprising degree of analgesia after being switched to even a relatively low dose, and the fact that others experience unanticipated toxicity [<a href="#rid32">32-34</a>]. Methadone is equally effective to <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> for cancer pain [<a href="#rid35">35</a>], and among the potential benefits of methadone use are its low cost, high oral bioavailability, and long duration of action; it is also the only long acting opioid available in a liquid formulation [<a href="#rid36">36,37</a>]. Because only approximately 20 percent of a dose is eliminated unchanged by the kidneys and there are no active metabolites, methadone, when dosed appropriately, may also be a particularly useful drug in patients with kidney disease. (See <a class="local">'Patients with kidney impairment'</a> below.)</p><p>The fact that <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> is effective in treating the opioid craving that occurs in those with opioid addiction has been used as a rationale for the use of this drug in those patients who develop aberrant drug-related behavior when given another mu agonist for cancer pain and for those who are a high risk of these behaviors before starting therapy. Although methadone can be used to treat pain in those with a history of opioid use disorder, but in doing so, clinicians must carefully document that the treatment is for pain and not for addiction. The targeted use of methadone to manage addiction is highly regulated in the United States and permitted only when the clinician is licensed to provide this treatment. (See  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Methadone: Opioid agonist'</a>.)</p><p>Although it is a valuable analgesic agent in patients with chronic cancer pain, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>'s unique pharmacology is also associated with a risk of unintentional overdose and the drug should be prescribed only by those who are familiar with its pharmacology. Guidelines for safe administration must be followed to reduce the risk of overdose. Clinicians who have questions about these guidelines or who lack experience may wish to seek assistance from a palliative care consultant before prescribing this drug.</p><p>The pertinent safety issues are summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Appropriate candidates</strong> – Not all patients are appropriate candidates for <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>; providers should perform a risk assessment before initiating methadone therapy. The following patients are potentially inappropriate candidates [<a href="#rid38">38</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patient lives alone, or has poor cognitive function and no responsible caregiver</p><p class="bulletIndent2"><span class="glyph">•</span>Obstructive or central sleep apnea</p><p class="bulletIndent2"><span class="glyph">•</span>Prognosis less than the projected time to achieve steady state (minimum 5 to 7 days)</p><p class="bulletIndent2"><span class="glyph">•</span>History of, or high risk for, QTc prolongation (including at risk for hypokalemia, hypomagnesemia, or structural heart disease)</p><p class="bulletIndent2"><span class="glyph">•</span>Clinical instability</p><p class="bulletIndent2"><span class="glyph">•</span>Multiple transitions in care likely</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Half-life and dosing titration</strong> – <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> has a variable half-life, which averages approximately 24 hours but ranges from 12 hours to almost one week [<a href="#rid32">32</a>]. Since five to six half-lives are required before steady state plasma concentrations are approached, the time required before a methadone regimen can be considered stable varies from several days to several weeks. Due to this highly variable and prolonged terminal half-life, methadone has the highest risk among opioids of accumulation and overdose during initial titration to effect, and during dose adjustment in chronic use. This has two clinical implications:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients, it is better to adjust the dose at intervals that are likely to allow the effects of the prior dose change to be realized (eg, every five to seven days rather than a shorter time frame) [<a href="#rid38">38</a>]. To start therapy in opioid-naïve patients, some palliative care clinicians prescribe a low fixed-dose regimen (eg, 2.5 mg orally two or three times per day) along with a short-acting oral opioid (eg, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> 5 to 10 mg or <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> 1 to 2 mg) that is dosed on an every-four-hour "as needed" basis [<a href="#rid38">38</a>]. The <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dose is then titrated every five to seven days (in increments of no more than 5 mg per day) and the need for the "as needed" opioid is expected to decline over time.</p><p></p><p class="bulletIndent2">Another approach to achieve safe titration of first-line <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, which we favor for patients with moderate to severe cancer pain, uses a low initial daily dose of methadone (2.5 to 5 mg per day) combined with a maximum of three daily rescue doses of 2.5 mg allowed every two to four hours as needed [<a href="#rid39">39</a>]. The "as needed" doses can be converted to fixed dosing two to three times daily once pain stabilizes. A palliative care consultation may be warranted for patients with severe pain who do not respond to this regimen within 48 hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitoring of the effects produced by a dose change must recognize the prolonged period during which the drug concentration is rising; one approach is a required "check-in" by the patient every two to three days for at least five to seven days or until the effects produced by the change in dose are observed to be stable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Difficulty in estimating equianalgesic doses for patients already receiving opioids</strong> – Perhaps even more challenging, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> is marketed in most of the world as a racemate containing a 1:1 mixture of the d- and the l-isomer. The d-isomer is a relatively potent N-methyl-D-aspartate (NMDA) inhibitor and not an opioid. NMDA antagonists are associated with nonopioid analgesia and with reversal of opioid tolerance. These effects may explain the observation that methadone can be far more potent than would be expected from published equianalgesic dosing tables, particularly when administered to patients with substantial prior opioid exposure. Concern about this unexpected potency must be addressed by selecting a cautious initial dose when switching from another drug to methadone.</p><p></p><p class="bulletIndent1">Guidelines from an expert panel for safe and appropriate use of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> in hospice and palliative care recommend the following approach to dosing of methadone in opioid-tolerant patients [<a href="#rid38">38</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving &lt;60 mg oral <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> per day or equivalent (OME), the initial <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dose should be no more than 7.5 mg oral methadone daily (eg, 2.5 mg three times daily).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving 60 to 199 mg OMEs and &lt;65 years of age, use a 10:1 conversion (ie, 10 mg OME:1 mg oral <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving ≥200 mg OME and/or patients &gt;65 years of age, use a 20:1 conversion (ie, 20 mg OME:1 mg oral <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>These and other guidelines also recommend converting to a <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dose no greater than 30 to 40 mg per day, regardless of the previous opioid dose [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dose should not be increased before five to seven days and should not be increased by more than 5 mg/day up to 30 to 40 mg/day, and then can be increased by 10 mg/day (after five to seven days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>QTc prolongation and need for ECG monitoring</strong> – <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> can prolong the QTc interval [<a href="#rid41">41-43</a>], a phenomenon that predisposes to a life-threatening cardiac arrhythmia, torsades du pointe. The clinical importance of this effect continues to be controversial, but it is prudent to consider the effect when starting therapy or increasing the dose. With the exception of patients with advanced illness and limited prognosis, for whom the need to address pain and avoid potentially burdensome monitoring [<a href="#rid40">40</a>] may exceed concerns about this risk, all patients should undergo a check of a baseline ECG prior to the start of methadone therapy [<a href="#rid38">38</a>]. A documented ECG from within the past year may suffice if the clinical status of the patient has been stable in the interim.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> should be used very cautiously in those with a QTc interval &gt;450 milliseconds; and generally should not be used if the QTc interval exceeds 500 milliseconds. For patients who have QTc prolongation, potentially reversible causes, such as hypokalemia or hypocalcemia, should be sought, and reversed, if present.</p><p></p><p class="bulletIndent1">Decisions about repeat ECGs should consider the baseline level of risk and the extent to which the monitoring is burdensome [<a href="#rid38">38</a>]. In those judged to need close monitoring, a repeat ECG may be done in several weeks, or after the dose is increased to approximately 40 mg/day and then again when the dose reaches approximately 100 mg/day [<a href="#rid40">40</a>]. For patients on a stable dose of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, a repeat ECG would be indicated only in the event of a new onset condition that may impact cardiac conduction or the administration of another drug that prolongs the QTc interval  (<a class="graphic graphic_table graphicRef57431" href="/d/graphic/57431.html" rel="external">table 3</a>). Although clear guidelines are lacking, it is reasonable to consider periodic additional ECGs if the dose continues to be increased. (See  <a class="medical medical_review" href="/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-drug interactions</strong> – <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is metabolized by CYP3A4 and CYP2B6 isoenzymes, and to a lesser extent, by other CYPs (2C19, 2C9, 2D6); drugs that function as inhibitors of CYP3A4 may increase methadone levels, and patients receiving concomitant treatment with one of these inhibitors should have methadone doses reduced. On the other hand, patients undergoing concomitant therapy with a CYP3A4 or 2B6 inducer may experience decreased methadone levels and reduced efficacy or withdrawal. A table listing several known inducers and inhibitors of CYP3A4 is provided  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1">Note that some drugs identified as strong CYP3A4 inhibitors can decrease <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> exposure (ie, opposite of expected effect) by an uncertain mechanism (eg, <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> boosted antiretroviral regimens including ritonavir-boosted <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>, <a class="drug drug_general" data-topicid="9982" href="/d/drug information/9982.html" rel="external">lopinavir-ritonavir</a> (combination pill), and ritonavir-boosted <a class="drug drug_general" data-topicid="9459" href="/d/drug information/9459.html" rel="external">tipranavir</a>). Thus, interactions should be carefully analyzed whenever drug therapy with methadone is adjusted. The <a class="external" href="/drug-interactions">drug interactions program</a> is available within UpToDate for this purpose.</p><p></p><p class="headingAnchor" id="H199136917"><span class="h2">Pure mu agonists rarely used for cancer pain</span><span class="headingEndMark"> — </span>Within the large group of pure mu agonist drugs, there are some that are of historical importance but are now rarely, if ever, used for cancer pain.</p><p class="headingAnchor" id="H3613538638"><span class="h3">Codeine</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) original analgesic ladder for treatment of cancer pain  (<a class="graphic graphic_figure graphicRef63298" href="/d/graphic/63298.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>], first published in the 1980s, referred to <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> as the prototype "weak" or "mild" opioid and recommended it for the first "rung" of the ladder as a preferred drug for moderate cancer pain. In the intervening years, however, these views have changed. The "weak" designation is now understood to be pharmacologically inappropriate, and although codeine could be used to treat moderate pain in the patient with limited to no opioid exposure, there is very limited evidence of a positive therapeutic index in any type of cancer pain [<a href="#rid44">44,45</a>]. It is now appreciated that any pure mu agonist, including those previously recommended for severe pain as the third "rung" of the analgesic ladder, could be effectively used for moderate to severe pain in opioid-naïve patients if started at a relatively low dose. This approach, which effectively eliminates the second "rung" of the analgesic ladder has been endorsed in guidelines for cancer pain management from the National Comprehensive Cancer Network (NCCN) and other organizations, including the European Association for Palliative Care [<a href="#rid46">46,47</a>] and the most recent guidelines for management of cancer pain from the WHO [<a href="#rid48">48</a>]. One study found that low-dose <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> (up to 30 mg daily) reduces pain significantly as compared with codeine (or <a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">tramadol</a>) with or without <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> in patients with moderate cancer pain, with similar tolerability and an earlier effect [<a href="#rid49">49</a>].</p><p><a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">Codeine</a> is available in combination with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>. These combination drugs restrict the amount of codeine that can be delivered because of concern about acetaminophen toxicity. The maximal daily dose of acetaminophen is recommended to be 3 g/day, and lower in those with known liver disease or risk factors for liver disease. (See  <a class="medical medical_review" href="/d/html/2798.html" rel="external">"Cancer pain management: Use of acetaminophen and nonsteroidal anti-inflammatory drugs", section on 'Hepatic toxicity'</a>.)</p><p>The use of <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> has also been questioned as more information appeared concerning genetic variation in its metabolism. The analgesic efficacy of codeine requires conversion to <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> via the CYP2D6 isoenzyme of the P450 hepatic enzyme system. CYP2D6 is highly polymorphic, with over 90 known allelic variants. Five to 10 percent of patients inherit a slow metabolizer phenotype, and they derive only limited or no therapeutic benefit from codeine because it will not be converted to its active moiety. Conversely, patients who are ultra-rapid metabolizers based on CYP2D6 genotype may have higher than expected morphine levels. This can lead to unintended toxicity. Similar effects have been described in patients receiving <a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">hydrocodone</a> and <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> but without the presumed clinical relevance perceived with codeine [<a href="#rid50">50,51</a>]. This variation in population genetics and the resulting uncertainty in effects when dosing begins [<a href="#rid52">52</a>], combined with the limited doses available in combination products, suggest that codeine should not be among the preferred drugs for cancer pain management.</p><p class="headingAnchor" id="H582409827"><span class="h3">Meperidine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">Meperidine</a> also is not preferred for use in the cancer pain population. It is metabolized into a compound (normeperidine) that is relatively toxic, and associated with tremulousness, delirium, and seizures. The metabolite has a longer half-life than the parent compound, and its concentration in blood rises for several days with repeated administration. Some patients will therefore develop normeperidine toxicity with repeated dosing over days. The metabolite is renally excreted, and its concentration increases (with greater risk of toxicity) in the setting of renal insufficiency. It is safer to select an alternative mu agonist for the management of chronic pain.</p><p class="headingAnchor" id="H1831799963"><span class="h2">Mixed-mechanism drugs: Tramadol and tapentadol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">Tramadol</a> and <a class="drug drug_general" data-topicid="9511" href="/d/drug information/9511.html" rel="external">tapentadol</a> are centrally acting analgesics whose mode of action is based both on the mu receptor binding and monoamine (serotonin and norepinephrine) reuptake blockade. Tramadol is widely used in some countries for moderate to severe cancer pain as an alternative to other opioids [<a href="#rid53">53,54</a>], but it is not used as commonly in the United States. Evidence is limited comparing either drug with other opioids in terms of either efficacy or tolerability in patients with cancer-related pain:</p><p class="bulletIndent1"><span class="glyph">●</span>A Cochrane review of four randomized trials of <a class="drug drug_general" data-topicid="9511" href="/d/drug information/9511.html" rel="external">tapentadol</a> compared with either placebo or an active control in 1029 adults with moderate to severe cancer pain concluded that there were insufficient data for pooling and statistical analysis of the four trials [<a href="#rid55">55</a>]. Overall, there was low quality evidence that tapentadol was no more or no less effective for pain relief than <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, and there was no advantage of tapentadol in terms of serious adverse events.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, a Cochrane review of 10 studies comparing <a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">tramadol</a> with either placebo or an active control in 958 adults with moderate to severe cancer pain concluded that there was limited, very low-quality evidence from randomized trials that tramadol produces pain relief in some adults with pain due to cancer, and very low-quality evidence that it is not as effective as <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid56">56</a>].</p><p></p><p>Based on this limited evidence and clinical experience, it is reasonable to conclude that either <a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">tramadol</a> or <a class="drug drug_general" data-topicid="9511" href="/d/drug information/9511.html" rel="external">tapentadol</a> could be used to treat cancer pain, but there is no known advantage in selecting one or the other over the pure mu agonist opioids that are conventionally used for this indication.</p><p class="headingAnchor" id="H1811738911"><span class="h2">Mixed agonist-antagonist drugs</span><span class="headingEndMark"> — </span>Because it has the capacity to induce withdrawal in opioid-tolerant patients, we reserve the use of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> for individuals with new-onset, moderate or severe cancer pain, and limited or no prior opioid treatment. It may be particularly useful in those with kidney impairment or when the potential for respiratory depression is a concern. Beside buprenorphine, we generally suggest not using drugs of the mixed agonist-antagonist group (<a class="drug drug_general" data-topicid="9179" href="/d/drug information/9179.html" rel="external">butorphanol</a>, dezocine, <a class="drug drug_general" data-topicid="9753" href="/d/drug information/9753.html" rel="external">pentazocine</a>, and <a class="drug drug_general" data-topicid="9676" href="/d/drug information/9676.html" rel="external">nalbuphine</a>) for cancer pain management.</p><p class="headingAnchor" id="H1759938722"><span class="h3">Buprenorphine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> is available as a treatment for opioid addiction and as a treatment for pain. (See  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Buprenorphine: Opioid agonist'</a>.)</p><p><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> has a complex pharmacology. It is a partial agonist at the mu opioid receptor, where it has very high affinity but relatively low intrinsic activity; it also produces some antagonism at the kappa receptor and other opioid receptors. As a partial mu agonist, it may have a ceiling effect for analgesia, but clinical experience with higher doses for the treatment of pain is limited, and the extent to which there is a clinically meaningful ceiling effect is uncertain. As a high-affinity drug, it can displace other mu agonists from the receptor and therefore has the ability to induce withdrawal if it is administered to patients who are already physically dependent on a pure mu agonist drug. This potential for abstinence when switching from another opioid to buprenorphine can be managed but is a problem that must be considered if buprenorphine treatment is being planned for a patient who may already be physically dependent on another opioid [<a href="#rid57">57</a>]. The problem of induced withdrawal does not exist or is minimal if buprenorphine is used in patients with very limited or no prior opioid treatment.</p><p><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> is available in multiple formulations. The transdermal formulation was developed for the treatment of chronic pain. In the United States, transdermal buprenorphine became available in 2010 (Butrans 5, 10, or 20 mcg/hour, all intended for seven-day use). The transdermal patch carries a warning against exceeding 20 mcg/hour due to the risk of QT prolongation. An alternative is a long-acting (daily or twice-daily administration) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D69df676c-0357-4e67-a92d-f6b337b34a2f&amp;token=VfQ7Y9OrMNcY%2FgioSKy5pLIRjMA6d%2BQXD01ymQNG%2FYThX70mS1%2BOPaJ%2B5uZ64tcj8f4Yk7RKogzFnmCLBjruvDSPDwYQmA%2B9%2FgRllQ%2Bbb222ZuMtToHuBidmbkj4hvSj&amp;TOPIC_ID=2814" target="_blank">buprenorphine buccal film</a>, which is initiated in the opioid-naïve patient at a dose of 75 micrograms once or twice daily if needed and well tolerated.</p><p>One of the advantages of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> is its relatively lower potential for respiratory depression compared with other agents [<a href="#rid58">58,59</a>]. However, experience with buprenorphine in the management of cancer pain is limited. Anecdotal reports, a few small prospective uncontrolled studies, and at least two small placebo-controlled randomized trials (conducted over a period of approximately two weeks) support at least short-term effectiveness and safety in patients with severe cancer-related pain [<a href="#rid60">60-64</a>]. Few comparative studies have been performed against other long-acting opioids, and the quality of the evidence from two such trials is uncertain [<a href="#rid65">65,66</a>]. Nonetheless, a 2009 consensus statement from an international panel with expertise in palliative care and pain treatment endorsed the use of transdermal buprenorphine where available [<a href="#rid67">67</a>].</p><p>Clinicians should be aware that there are a number of reports of dental problems associated with the use of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> formulations that are dissolved in the mouth, including the buccal formulation. (See  <a class="medical medical_review" href="/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain", section on 'Buprenorphine for chronic pain'</a>.)</p><p>Given the limited evidence, the doses of transdermal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> that are available in the United States, and the need to manage the risk of withdrawal when switching to buprenorphine from another pure mu agonist opioid, it is reasonable to consider buprenorphine only in those who are relatively opioid naïve, typically patients with new-onset, moderate, or severe cancer pain. More recent reviews, including one used to inform the work of an expert panel, note that buprenorphine pharmacology may make it a favorable drug for chronic pain treatment [<a href="#rid57">57,68</a>] and encourage further consideration of its use. This applies to cancer pain as well. For example, one setting in which buprenorphine may be particularly useful is in the cancer patient with kidney impairment who is opioid-naïve and has moderate or severe cancer pain, especially when there is a concern for respiratory depression [<a href="#rid69">69,70</a>]. (See <a class="local">'Patients with kidney impairment'</a> below.)</p><p class="headingAnchor" id="H1211925218"><span class="h3">Other drugs</span><span class="headingEndMark"> — </span>Besides <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, we generally suggest not using drugs of the mixed agonist-antagonist group (<a class="drug drug_general" data-topicid="9179" href="/d/drug information/9179.html" rel="external">butorphanol</a>, dezocine, <a class="drug drug_general" data-topicid="9753" href="/d/drug information/9753.html" rel="external">pentazocine</a> and <a class="drug drug_general" data-topicid="9676" href="/d/drug information/9676.html" rel="external">nalbuphine</a>) for cancer pain management. This is because of a ceiling effect for analgesia, and the capacity to induce withdrawal when administered to patients already receiving other opioids of the mu agonist class.</p><p class="headingAnchor" id="H16"><span class="h1">PRACTICAL CONSIDERATIONS IN OPIOID USE</span></p><p class="headingAnchor" id="H17"><span class="h2">Prescribing restrictions and risk management</span><span class="headingEndMark"> — </span>Opioids have the potential for misuse, abuse and addiction, and are regulated by government. In the United States, these drugs are designated "controlled substances" under a federal law known as the Controlled Substances Act  (<a class="graphic graphic_table graphicRef66064" href="/d/graphic/66064.html" rel="external">table 5</a>). Clinicians are responsible for prescribing in a manner consistent with federal and state laws and regulations, and also have responsibility for implementing best practices that minimize the risk of abuse-related outcomes. Issues in risk management when these drugs are prescribed are addressed elsewhere. (See  <a class="medical medical_review" href="/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids", section on 'Risk assessment and management for patients receiving opioids'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Selecting the opioid</span><span class="headingEndMark"> — </span>The literature on opioid comparative efficacy and effectiveness [<a href="#rid71">71</a>] precludes an evidence-based approach to opioid selection. Accordingly, recommendations continue to be based on clinical experience. The following represents of general approach:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are opioid naïve and have pain severe enough to warrant opioid therapy can be offered one of the opioid-nonopioid combination products or one of the pure mu agonists at a low initial dose.</p><p></p><p class="bulletIndent1">If acetaminophen-oxycodone is used, the dose of the opioid usually is 5 mg per tablet; a lower dose (2.5 mg per tablet) should be considered in older or very frail adults  (<a class="graphic graphic_table graphicRef95621" href="/d/graphic/95621.html" rel="external">table 6</a>).</p><p></p><p class="bulletIndent1">If acetaminophen-hydrocodone is used, the usual dose of the opioid is 5 to 7.5 mg per tablet; 2.5 and 10 mg <a class="drug drug_general" data-topicid="8531" href="/d/drug information/8531.html" rel="external">hydrocodone-acetaminophen</a> combinations are also available. The initial prescription usually is one to two tablets every three hours, as needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with cancer pain who are relatively opioid naïve, we prefer a single-entity pure mu agonist at a low dose. Options include oral <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> (5 to 10 mg orally every three to four hours), oral <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> (2.5 to 5 mg orally every four hours), <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> (1 to 2 mg orally every three to four hours), or transdermal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> (12 mcg/hour every 72 hours). (See <a class="local">'Pure mu agonists commonly used for cancer pain'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is another option. To start therapy in opioid-naïve patients, some palliative care clinicians prescribe a low fixed-dose regimen (eg, 2.5 mg orally two or three times per day) along with a short-acting oral opioid (eg, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> 5 to 10 mg or <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> 1 to 2 mg) that is dosed on an every-four-hour "as needed" basis [<a href="#rid38">38</a>]. The methadone dose is then titrated every five to seven days (in increments of no more than 5 mg per day) and the need for the "as needed" opioid is expected to decline over time. (See <a class="local">'Methadone'</a> above.)</p><p></p><p class="bulletIndent1">Transdermal or buccal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> also should be considered. (See <a class="local">'Buprenorphine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a patient is given a short-acting drug and needs several doses per day (or if a bedtime dose does not permit uninterrupted sleep through the night), a switch to a long-acting formulation is commonly undertaken to improve convenience and adherence. There is no evidence that any one of the commonly used, long-acting formulations that are available in the US, including <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a>, <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>, and <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> is more likely to be effective than any other [<a href="#rid72">72</a>]. Selection usually is determined by the patient's prior experience with opioids, the clinician's experience, cost and availability, and formulation.</p><p></p><p class="bulletIndent1">As noted, there is some evidence that transdermal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> is less constipating than oral <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> and the former drug may be preferred if constipation has been a challenging problem. If an oral formulation is given, some patients prefer once-daily dosing (eg, with <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> or morphine) rather than twice-daily dosing (eg, with <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>).</p><p></p><p class="bulletIndent1">Although <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> is far less costly and can be used effectively as a long-acting drug for cancer pain (usually requiring oral dosing three times per day and sometimes twice a day), the challenges inherent in the safe prescribing of this drug suggest that it should be considered a first-line treatment option only by clinicians experienced in its use. Clinicians with limited experience may consider obtaining a consultation from a specialist in palliative care or pain management to assist with the initiation of methadone therapy. Even experienced clinicians usually consider methadone only in the event that trials of one or more of the other pure mu agonist drugs fail to provide an adequate balance between analgesia and side effects. (See <a class="local">'Methadone'</a> above and <a class="local">'Switching to methadone'</a> below.)</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Patients with kidney impairment</span><span class="headingEndMark"> — </span>The following considerations are important when managing chronic pain in cancer patients with significant kidney impairment [<a href="#rid73">73-75</a>]. It should be noted that these recommendations are largely based upon pharmacokinetics and clinical experience; there is very little high-quality clinical evidence to support opioid choice in patients with kidney impairment [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H535616638"><span class="h3">Drugs to avoid</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">Meperidine</a> (Demerol) should not be used, since its active metabolite, normeperidine, accumulates with renal dysfunction and can cause serious central nervous system (CNS) toxicity. Given the prevalence of renal dysfunction in the cancer population, and the potential for normeperidine toxicity even in those with normal renal function, particularly if the dose is increased to manage poorly controlled pain, meperidine is generally not preferred for cancer pain management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> is metabolized in part to a potent opioid metabolite, morphine-6-glucuronide, and a metabolite, morphine-3-glucuronide, which is associated with neurotoxicity. These metabolites are renally excreted and there is concern that their accumulation in patients with renal insufficiency may lead to unanticipated changes in morphine potency or side effects [<a href="#rid76">76</a>]. Although the current evidence for these neurotoxic effects consists only of very-low-quality studies with conflicting findings [<a href="#rid77">77</a>], morphine should be administered carefully in the setting of kidney impairment. Close monitoring for neurotoxic effects (eg, sedation, cognitive impairment, myoclonus) is particularly important if kidney function is changing; in this situation, the decision to use morphine should be reconsidered. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">Oxycodone</a> may be used among patients with kidney impairment but, like <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, raises concerns about the impact of renally-excreted metabolites that may accumulate in this setting. These metabolites, noroxycodone and <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a>, are produced in the liver and may have relatively high concentration in patients with advanced kidney impairment [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/d/html/93774.html" rel="external">"Management of chronic pain in advanced chronic kidney disease", section on 'Drugs that should be avoided'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> and <a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">tramadol</a> can accumulate in patients with kidney impairment, enhancing both their effects and side effects.</p><p></p><p class="headingAnchor" id="H476180598"><span class="h3">Preferred drugs</span><span class="headingEndMark"> — </span>Preferred opioids in the setting of kidney impairment may be those whose metabolism does not pose an increased risk:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">Hydromorphone</a>, for example, has active metabolites but these are produced in relatively low concentration (compared with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>) and may be less likely to cause unanticipated effects in the setting of kidney impairment. Although this drug is often selected for this reason, it is important to recognize that accumulating metabolites can cause problems, particularly with higher doses [<a href="#rid79">79-81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">Fentanyl</a>, <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, and <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> lack active metabolites and also are considered in the setting of kidney impairment on this basis. Although methadone is another option for patients with chronic kidney impairment, concerns about the risks associated with methadone, however, speak against the use of this drug in patients who may be metabolically unstable (ie, acute kidney impairment, severe chronic kidney impairment), and clinicians may prefer to use fentanyl, buprenorphine, or <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> in patients with kidney impairment. (See <a class="local">'Methadone'</a> above and <a class="local">'Buprenorphine'</a> above.)</p><p></p><p class="headingAnchor" id="H733130714"><span class="h2">Patients with chronic liver disease</span><span class="headingEndMark"> — </span>Most opioids are at least partially metabolized by the liver, complicating their use in patients with chronic liver disease [<a href="#rid82">82</a>]. However, safe prescribing of analgesics for patients with chronic liver disease is possible as long as a few general guidelines are followed  (<a class="graphic graphic_table graphicRef90196" href="/d/graphic/90196.html" rel="external">table 7</a>). In general:</p><p class="bulletIndent1"><span class="glyph">●</span>Lower initial starting doses for most opioids are warranted in patients with chronic liver disease, and clinicians should be cautious prescribing opioids at "regular" dosing intervals until patients have demonstrated that drug level does not become too high during the chosen dosing interval. As the liver disease progresses, prolonged dosing intervals may be needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">Codeine</a> and <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">meperidine</a> should be avoided entirely in patients with chronic liver disease. Codeine is a prodrug that is converted to <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> via the CYP2D6 isoenzyme of the P450 hepatic enzyme system; pain control may be compromised by diminished metabolism. In hepatic disease, meperidine clearance is reduced, and the half-life is prolonged.</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Management of breakthrough pain</span><span class="headingEndMark"> — </span>Breakthrough pain is a transitory severe acute pain that occurs on a background of chronic pain that is otherwise adequately controlled by a sustained release, long-acting, transdermal or parenteral opioid regimen [<a href="#rid83">83,84</a>]. Given its high prevalence in patients with cancer pain, and its negative clinical consequences, a treatment approach known as "rescue" dosing has become a widely accepted approach. Management of other types of acute pain (eg, from a new injury or surgical procedure) in patients chronically using opioids for non-cancer pain is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain"</a>.)</p><p>Clinically significant breakthrough pain usually is managed by prescribing a rescue drug, which is usually a short-acting opioid offered on an as-needed basis. The rescue dose is separate from the fixed scheduled opioid regimen and may be used by the patient to treat episodic acute pain or, at times, to prevent its occurrence. In most situations, the rescue drug is chosen to be one of the single entity oral opioid formulations, such as immediate-release <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, or <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a>. Based on clinical experience, a typical dose chosen for the rescue is in the range of 5 to 15 percent of the basal daily requirement of opioid [<a href="#rid85">85</a>]. (See <a class="local">'Practical considerations in opioid use'</a> above.)</p><p>If the dose selected for rescue dosing does not yield satisfactory effects, the dose should be increased as necessary. If the dose of the fixed scheduled opioid regimen is changed, the usual approach is to proactively increase or decrease the oral rescue dose so that it remains roughly proportional to the baseline dose (ie, in the range of 5 to 15 percent of the basal daily requirement of opioid).</p><p>Breakthrough pain also may be targeted with one of the newer rapid-onset, transmucosal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> formulations, which are specifically indicated for cancer-related breakthrough pain in patients who are opioid tolerant. In the United States formulations of transmucosal fentanyl include an oral transmucosal fentanyl lozenge (Actiq) and an effervescent fentanyl buccal tablet (Fentora). Additional formulations may be available in other countries. For instance, an immediate-release transmucosal tablet formulation (Abstral) is available in some European countries  (<a class="graphic graphic_table graphicRef111217" href="/d/graphic/111217.html" rel="external">table 8</a>). In the United States, all of these products, including generics, have a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Frems%2Findex.cfm%3Fevent%3DRemsDetails.page%26REMS%3D60&amp;token=sAuLGS55036cp5jwsCRDBdgax%2Bqq59ITNRQTl1tb3gPhhIO5KAoJJsh%2BJ4yXyu7wIM2pdrwkHZQz9ZYC3QqzWR8hpsAQHgoxMIhEAx54FWkE8AmWo0F%2BfVFr5%2FL1KRQt&amp;TOPIC_ID=2814" target="_blank">mandatory shared risk evaluation and mitigation strategy (REMS)</a>, the purpose of which is to reduce the risk of misuse and unintentional overdose. To prescribe any of these drugs, clinicians must complete online education, and each patient treated requires registration of the patient, clinician, and pharmacist. Because of data suggesting that transmucosal fentanyl preparations were still being prescribed to opioid-naïve patients, in December 2020, additional regulations beyond education and registration were put into place by the US Food and Drug Administration, requiring that opioid tolerance be verified and documented by both the prescriber and the outpatient pharmacy, prior to each individual prescription [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids"</a>.)</p><p>Studies of these transmucosal immediate-release <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> (TIRF) formulations have established efficacy, with an onset of effect that is faster than that expected from oral formulations [<a href="#rid87">87-93</a>]. Comparative effectiveness against one of the typical short-acting oral formulations has been determined for the nasal and oral fentanyl formulations [<a href="#rid88">88,90,94</a>], at least in terms of the onset of pain relief. Sublingual fentanyl may also be preferred by patients over subcutaneous <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid95">95</a>]. Studies that have compared the different TIRF drugs are limited [<a href="#rid96">96</a>].</p><p>Based on the existing comparative data and clinical observations, it is likely that the more rapid onset of the TIRF formulations are highly favorable for some patients. Due to cost and limited experience, however, these drugs are generally considered only after a patient has demonstrated a poor response to an oral rescue dose. Patients with very-rapid-onset pain might also be considered for an early trial. Given the lack of comparative data, there are no recommendations about which of the many formulations might be preferable.</p><p>Regardless of the formulation selected, the recommended starting dose is the lowest or next-to-lowest available. This recommendation, which is contrary to the use of proportionate dosing that characterizes oral rescue doses, is made because controlled trials have not confirmed that a dose proportionate to the baseline dose is needed to observe effects. Although some experts do endorse the use of proportionate dosing with the TIRFs, safety considerations suggest that initiation of therapy with a low dose followed by dose titration is appropriate.</p><p class="headingAnchor" id="H21"><span class="h2">Selecting the route of administration</span></p><p class="headingAnchor" id="H22"><span class="h3">Oral</span><span class="headingEndMark"> — </span>The oral route is usually preferred for chronic treatment of cancer pain because of convenience and flexibility. Many cancer patients require alternative routes of analgesic administration at some time during the course of their illness.</p><p>In most patients, orally administered, non-transmucosal, immediate-release formulations have a peak analgesic effect at 1 to 1.5 hours, while the analgesic peak with most modified-release oral formulations is approximately three to five hours.</p><p>Some of the immediate release opioids, such as <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> and <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, are also available in liquid formulations, which may be useful for patients with odynophagia or dysphagia or who can only receive medications through feeding tubes.</p><p>Oral modified-release medications should never be crushed because of the potential for toxicity related to the sudden release of the full dose in the tablet or capsule (a phenomenon known as "dose dumping"). Several of the modified-release opioids can "dose dump" if coadministered with alcohol, which can dissolve the matrix in which the drug is embedded. It is best to inform patients that alcohol consumption should be avoided during the hours around administration of each dose.</p><p>Use of the oral route may not be feasible in patients with oral mucositis, dysphagia, bowel obstruction, or severe nausea. Some of the modified-release <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> formulations (eg, Kadian) are capsules that can be opened and sprinkled on food without changing the delivery characteristics; this can permit the administration of a modified-release drug through a feeding tube, if necessary, but the pellets can clog all but the largest feeding tubes. Liquid <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> or transmucosal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> or <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, for those with adequate fat reserves, may be better choices for those patients. (See <a class="local">'Transdermal'</a> below.)</p><p class="headingAnchor" id="H23"><span class="h3">Transdermal</span><span class="headingEndMark"> — </span>Transdermal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> is widely used for chronic pain. Each transdermal patch provides 48 to 72 hours of relatively stable drug delivery for most patients. (See <a class="local">'Fentanyl'</a> above.)</p><p>Transdermal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> may be preferred over an orally administered opioid in the setting of poor gastrointestinal tract absorption or dysphagia, or if constipation is an issue. Transdermal fentanyl may also be preferred by patients who are distressed by the number of tablets required to manage medical disorders and for those whose adherence to treatment would be improved by use of the transdermal route.</p><p>Transdermal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> may not be effective in patients lacking adequate adipose tissue over which the patch can be placed. In such patients, without an adequate subcutaneous drug reservoir, fentanyl serum levels may never become therapeutic, presumably because the drug is not delivered to the blood as a continuous infusion and the liver metabolizes the drug as it is presented to it. Patients with low albumin levels who have frequent infections are at risk for toxicity from transdermal fentanyl because of sudden increases in the free fraction of fentanyl along with increased absorption from the reservoir when the patient's temperature exceeds 102 degrees F.</p><p>Transdermal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> is available in some countries, including the United States. As discussed, efficacy in cancer pain has been addressed in six randomized trials, in which transdermal buprenorphine was compared with placebo, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, or transdermal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> [<a href="#rid23">23,62,64,66,97,98</a>]. Although efficacy is likely, the studies were not designed to address long-term effectiveness, making the results difficult to interpret [<a href="#rid99">99</a>]. The available data suggest that transdermal buprenorphine may be useful, as in patients who are relatively opioid naïve and do not have severe pain requiring rapid dose titration; it is not generally considered first line due to the limited experience. (See <a class="local">'Buprenorphine'</a> above.)</p><p class="headingAnchor" id="H24"><span class="h3">Rectal</span><span class="headingEndMark"> — </span>Occasional patients are treated with rectal administration of an opioid [<a href="#rid100">100</a>]. In the United States, short-acting rectal formulations are available for <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> (5, 10, 20, 30 mg rectal suppositories), <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> (3 mg) and <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a> (5 mg). In addition, there is limited anecdotal experience in the rectal use of a long-acting modified-release formulation [<a href="#rid101">101,102</a>].</p><p>The potency of rectally administered opioids is believed to approximate oral dosing, but absorption is variable and relative potency may be higher or lower than expected [<a href="#rid102">102,103</a>]. For this reason, a switch from oral to rectal dosing is usually accompanied by a reduction in the equivalent dose. (See <a class="local">'Equianalgesic opioid dose conversion'</a> below.)</p><p class="headingAnchor" id="H25"><span class="h3">Subcutaneous and intravenous administration</span><span class="headingEndMark"> — </span>Among patients with a progressive illness like cancer, it is commonplace for a pain regimen that was initially administered via an oral or transdermal route to be switched, at least temporarily, to continuous intravenous (IV) or subcutaneous (SC) infusion. As an example, this switch may happen if a patient who has been on a chronic stable doses of a long-acting opioid is hospitalized with an acute pain crisis. The intramuscular route is not generally used because it is painful and provides no pharmacological advantage.</p><p>Continuous SC infusion can be easily accomplished using a "butterfly" catheter inserted under the skin of the chest wall or abdomen; the needle can remain in place for a week or more, and any drug with an injectable formulation can be administered in this way [<a href="#rid104">104</a>]. <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is not preferred via the SC route as it can act as an irritant to the skin.</p><p>In order to maintain the comfort of an infusion site, the SC infusion rate should not exceed 5 mL/hour. Higher volumes can be delivered, however, if <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> is added to the infusion. In order to limit the total volume of injectate, <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> may be chosen over <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> and <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> because of its greater water solubility [<a href="#rid105">105</a>]; it is commercially available in a relatively concentrated 10 mg/ml solution for injection.</p><p>Patients receiving continuous IV or SC infusion may benefit from access to intermittent administration of a short-acting drug for breakthrough pain. The IV route has the most rapid onset of action. When administered as an IV bolus, some drugs, such as <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>, have a peak onset almost immediately, whereas other drugs, such as <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, may require 15 to 30 minutes because of the time required to penetrate the blood-brain barrier.</p><p class="headingAnchor" id="H622751254"><span class="h4">Patient-controlled analgesia</span><span class="headingEndMark"> — </span>A pump with a patient-controlled analgesia (PCA) option can be used to administer continuous infusion by either the IV or SC route, and thereby facilitate the option of "rescue doses." PCA devices are programmed for the size of the dose, the minimum time between doses (lockout interval), and the cumulative dose allowed in one or four hours (several times higher than the anticipated need). Some pumps allow separate programming of doses delivered by the patient or the clinicians, respectively.</p><p>While it is widely recommended [<a href="#rid46">46,47</a>], most of the evidence supporting the benefit of PCA over other methods of titration has come mainly from reports of single arm trials, small cohorts, and literature review articles [<a href="#rid106">106-110</a>]. However, at least one small randomized trial (n = 214 patients) supports better outcomes for PCA versus non-PCA <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> titration for severe pain in opioid tolerant patients, with a significantly shorter time to successful titration of hydromorphone dose with PCA [<a href="#rid111">111</a>]. Notably, for opioid-naïve patients (43 percent of those enrolled), the time to achieve successful titration of hydromorphone dose was not significantly different with PCA as compared with a non-PCA approach.</p><p>Although safe and efficacious PCA settings for <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, and <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> are widely accepted when this modality is used for acute postoperative pain, the settings are usually quite different when PCA is selected for cancer pain. Patients typically have a prior opioid regimen that is switched to an appropriate dose of a continuous infusion. The supplemental rescue dose administered via the PCA pump is selected to be roughly in the range of 5 to 15 percent of the prior total daily dose. In contrast to acute pain, the treatment of which often involves access to PCA delivered doses every six to seven minutes, the so-called lockout period when PCA is used to deliver rescue doses to opioid tolerant patients during chronic infusion may be longer, such as 10 to 30 minutes, if higher rescue doses are needed to provide pain relief.</p><p class="headingAnchor" id="H26"><span class="h3">Intrathecal and intraspinal administration</span><span class="headingEndMark"> — </span>Properly selected patients can benefit from interventional pain management approaches, such as intraspinal opioid administration (epidural or intrathecal, collectively called "neuraxial" analgesia) [<a href="#rid112">112</a>]. A systematic review of intraspinal techniques for cancer pain [<a href="#rid113">113</a>], which included one randomized trial comparing neuraxial analgesia via an implanted programmable pump against conventional analgesic therapy [<a href="#rid114">114</a>], concluded that intraspinal therapy can be equally or more effective than systemic analgesic therapy and yield analgesia with relatively fewer side effects.</p><p>Patients whose pain has not responded to optimally administered systemic opioid therapy should be considered for referral to a specialist in pain management for evaluation of this and other neuraxial techniques, among other interventional strategies for pain management. (See  <a class="medical medical_review" href="/d/html/14248.html" rel="external">"Interventional therapies for chronic pain"</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">Dose titration</span><span class="headingEndMark"> — </span>Following selection of a starting dose, adjustment is almost always required to optimize an opioid regimen and sustain its benefits over time. Dose individualization is the key to optimizing the outcomes of opioid therapy [<a href="#rid115">115-119</a>].</p><p>Continuous or frequently recurrent pain is most effectively managed with a fixed schedule, "around-the-clock" opioid regimen, which is usually combined with "as needed" rescue doses for breakthrough pain. Dose titration to achieve adequate pain relief from a fixed scheduled regimen is attainable in most cases.</p><p>Conventionally, dose titration is accomplished in one of two ways. The fixed scheduled dose can be increased by 30 to 100 percent of the total dose taken in the prior 24 hour period (with the percent increase informed by the severity of the pain, the degree of medical frailty or comorbidities that may increase opioid risk, and the existing formulations). Alternatively, the fixed scheduled dose can be increased by a daily amount that is determined by averaging the total amount of supplemental rescue medication taken during the prior few days (adjusted for the estimated equianalgesic potency, if needed  (<a class="graphic graphic_table graphicRef111216" href="/d/graphic/111216.html" rel="external">table 9</a>)). These step-wise methods of dose escalation ensure safety as the dose is increased. Caution is needed, however, if the increase in the baseline dose is not expected to be accompanied by a reduction in the use of rescue medication (such as may be the case if rescue is needed for predictable painful events, like dressing changes). If the increase in the baseline dose is relatively high, such as &gt;50 percent, this increment combined with the unchanging use of rescue could lead to side effects associated with an increase in total dose higher than intended.</p><p>As a general rule, the dose of an opioid can be increased until a favorable balance between analgesia and side effects is obtained, or the patient develops intolerable and unmanageable side effects. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain"</a>.)</p><p>Although it is generally understood that dose escalation can continue without regard to a maximum dose, the need for a relatively high dose (eg, a dose equivalent to &gt;200 mg <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>) in an individual patient should prompt a careful reassessment. Some patients will have pain that does not appear to be diminishing even as doses increase and others may demonstrate troubling behaviors or incipient side effects like mild signs of cognitive impairment. Some have an excessive pill burden. These observations may suggest consideration of an alternative strategy.</p><p>Ideally, the interval between dose escalations should be long enough to allow a new steady state (which requires five to six half-lives, irrespective of the route or drug) to be approached following each dose adjustment:</p><p class="bulletIndent1"><span class="glyph">●</span>Two to three days for the modified-release oral formulations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three to six days for the transdermal patch.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although five days is usually sufficient to judge the full effect of a change in <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dose, the variability of this drug's half-life means that occasional patients will require much longer periods (up to several weeks) to ensure that effects have become stable. (See <a class="local">'Methadone'</a> above.)</p><p></p><p>For patients with severe pain, more rapid dose escalation is needed. However, when doses are escalated at intervals shorter than those necessary to approach steady state (five to six half-lives), there is a possibility of "overshooting." In this phenomenon, the patient undergoing rapid dose titration reports benefit, but continuation of the successful dose later results in toxicity as drug levels continue to rise toward steady state.</p><p>When rapid dose titration is needed to address poorly controlled pain, the risk of overshooting should be assessed. The risks are greater when the drug has a relatively long half-life (the greatest concern is with <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>) or the patient is medically frail. In some cases, hospitalization should be considered for the express purpose of monitoring aggressive escalation of the dose. Hospitalization during a period of particularly intense pain, or "pain crisis," is a medically appropriate option for selected patents.</p><p>As the dose of the fixed schedule opioid regimen is increased, the dose of the "rescue" drug also must be increased. In most cases, the dose of this short-acting medication should remain in the range of 5 to 15 percent of the total daily dose [<a href="#rid120">120</a>]. The exception to this is found when using the rapid-onset transmucosal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> formulations, which may have effects at doses that are not proportional to the fixed schedule dose [<a href="#rid121">121</a>]. In the case of these drugs, the starting dose should be low and dose titration proceeds with the commercially available dose units, stopping at a level associated with benefit. (See <a class="local">'Management of breakthrough pain'</a> above.)</p><p>The following case illustrates the stepwise methods for dose titration, applying these approaches to a patient receiving relatively high doses of an opioid.</p><p>A patient with slowly progressive breast cancer, who has undergone several periods of opioid dose adjustment because of worsening pain, is taking long-acting <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> 240 mg twice daily plus "rescue" doses consisting of five tablets of short-acting oxycodone 5 mg (25 mg per dose); on each day, approximately four rescue doses are needed. She has no side effects except for constipation, which has been controlled with laxatives. When her pain worsens again, she is assessed, and in the absence of unmanageable side effects, the decision is made to further escalate the dose. Her total daily dose of oxycodone has been 480 mg (long-acting) plus 100 mg (rescue) or 580 mg. There are two approaches to dose increase:</p><p class="bulletIndent1"><span class="glyph">●</span>One approach to increasing the dose is to add 30 to 50 percent to the total daily dose (30 percent of 580 = 174). The largest <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> tablet is 80 mg, and an increase of 30 percent can be easily accomplished by adding one 80 mg tablet to each of the fixed doses: a fixed regimen of 320 mg twice daily. The rescue dose can be changed to 35 mg per dose at the same time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The alternative approach, adding the total daily rescue dose, or 100 mg/day in this case, to the fixed scheduled dose yields a more conservative outcome but still one in the range to be useful.</p><p></p><p>Both strategies are appropriate and safe; any smaller increment is unlikely to be beneficial.</p><p>This case also illustrates a typical pattern observed during long-term treatment of cancer pain. The opioid dose is usually maintained for a prolonged time, unless there is progression in the pain-producing pathology. Recurrent pain or the new occurrence of side effects necessitates a new assessment, and often, another period of dose titration. Although the use of relatively high doses requires careful reevaluation, some patients continue to benefit if stepwise dose titration is continued.</p><p>It is worth noting that updated 2022 guidelines for prescribing opioids for chronic pain from the United States Centers for Disease Control (CDC) recommend careful consideration of the risks and benefits of therapy for daily doses at or above 50 mg (<a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> equivalents)<em> </em>[<a href="#rid122">122</a>]; however, these guidelines specifically exclude patients with active cancer, and other guidelines such as from the National Comprehensive Cancer Network (NCCN) and ASCO do not provide a daily ceiling dose for patients with active cancer or cancer survivors [<a href="#rid119">119,123</a>]<em>. </em>(See  <a class="medical medical_review" href="/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids"</a>.)</p><p class="headingAnchor" id="H28"><span class="h2">Pain that respond poorly to opioids alone</span><span class="headingEndMark"> — </span>When a patient's pain is poorly responsive to an opioid, ie, when a favorable balance between analgesia and side effects cannot be obtained and treatment-limiting side effects occur without adequate pain control, it might be related to the type of pain (neuropathic pain may less likely to respond adequately to opioids alone than pain related to ongoing tissue injury) or other issues, such as a high propensity to develop side effects (eg, presence of preexisting cognitive impairment, frail older adults). (See  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Patients with neuropathic pain'</a>.)</p><p>Clinicians must be attuned to the occurrence of opioid poorly responsive pain [<a href="#rid124">124,125</a>], recognize it promptly, assess potential contributors  (<a class="graphic graphic_table graphicRef90182" href="/d/graphic/90182.html" rel="external">table 10</a>), and be prepared to offer an alternative strategy for pain management.</p><p>The first step is to reassess the patient for factors that may be driving the pain or predisposing to side effects. This assessment should include questions about psychosocial and spiritual concerns. If aberrant substance use is suspected, a detailed history relevant to aberrant substance use outcomes (nonadherence, addiction, and diversion) should be done. (See  <a class="medical medical_review" href="/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids", section on 'Risk assessment and management for patients receiving opioids'</a>.)</p><p>A physical examination should be completed, and diagnostic studies ordered, as indicated.</p><p>If a potentially treatable etiology of the poorly responsive pain cannot be identified, and it is clear that additional analgesic benefit is not being derived from dose escalation of a single opioid, a new plan of care must be developed. This may involve any one of a large number of options  (<a class="graphic graphic_table graphicRef75273" href="/d/graphic/75273.html" rel="external">table 11</a>) [<a href="#rid126">126</a>], each of which must be evaluated in terms of benefit and burden, within the context of the larger goals of care. Strategies for prevention and management of common opioid side effects are covered elsewhere. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain"</a>.)</p><p class="headingAnchor" id="H3113237550"><span class="h3">How to perform opioid rotation</span><span class="headingEndMark"> — </span>A common approach to the management of poorly responsive pain is known as "opioid rotation," which is defined as a switch from one opioid to another in an effort to provide better outcomes. The rationale for this strategy is based on pharmacologic and clinical observations that suggest that a change in drug is more likely than not to improve the balance between pain relief and side effects [<a href="#rid127">127</a>].</p><p class="headingAnchor" id="H29"><span class="h4">Equianalgesic opioid dose conversion</span><span class="headingEndMark"> — </span>Each opioid drug has a different potency, defined as the dose necessary to produce a given effect. When switching from one opioid to another, the starting dose of the new drug must be informed by the difference in their relative potencies. The starting dose of the replacing drug must be close enough to its predicted equianalgesic dose to prevent the development of withdrawal (if the dose of the new drug is too low) or unintentional overdose (if it is too high). Equianalgesic dose tables  (<a class="graphic graphic_table graphicRef111207" href="/d/graphic/111207.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef111216" href="/d/graphic/111216.html" rel="external">table 9</a>) have been developed as a means for comparing potencies among opioids.</p><p>Although it is essential to know the approximate equianalgesic dose between drugs when switching from one to the other, this is only the first step. Although the relative potency estimates represent the best science after more than 40 years of studies [<a href="#rid128">128</a>], application of the ratios in the equianalgesic dose table to the clinical setting must be done cautiously because of the following issues:</p><p class="bulletIndent1"><span class="glyph">●</span>Individual patients may not have the characteristics of those who were included in the relative potency studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is very large individual variation in drug metabolism and pharmacodynamics, indicating that even patients with similar characteristics may have very different responses to different drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tolerance to adverse effects during long-term treatment does not occur to different drugs in the same way. This "incomplete cross-tolerance" means that a new drug can have unexpectedly strong effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because of variations in drug absorption, a dose reduction may be needed when switching from one route of administration to another (eg, from oral to rectal dosing), even for the same drug. (See <a class="local">'Rectal'</a> above.)</p><p></p><p>To ensure that opioid rotation is done safely, clinical guidelines have been developed that incorporate reductions in the calculated equianalgesic dose [<a href="#rid129">129</a>]. These reductions have been conceptualized as ranges, one automatic and one based on specific patient characteristics, and clinical judgment must be used to apply them  (<a class="graphic graphic_table graphicRef59062" href="/d/graphic/59062.html" rel="external">table 12</a>) [<a href="#rid130">130</a>].</p><p class="headingAnchor" id="H29772191"><span class="h5">Switching to methadone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is an effective drug for cancer pain [<a href="#rid35">35</a>], and among its potential benefits are low cost, high oral bioavailability, and long duration of action; it is also the only long acting opioid available in a liquid formulation. (See <a class="local">'Methadone'</a> above.)</p><p>However, given the complexity of this drug's pharmacokinetic profile, a change from any of the pure mu agonist drugs to <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> is the most challenging aspect of opioid rotation, and the optimal way to switch is debated. It is clear that the ratios that appear on standard equianalgesic dose tables, which were derived from studies of patients receiving relatively low doses, may be far from the actual methadone dose required to achieve a good outcome. In one study, for example, there was no correlation between high <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> milligram equivalent (MME) doses (ie, &gt;1200 mg/day) and the final methadone dose after stabilization in patients being rotated to methadone [<a href="#rid131">131</a>]. The authors suggested a fixed maximum methadone dose of no more than 30 mg/day for patients receiving &gt;1200 mg/day of morphine or MMEs.</p><p>We agree with guidelines from an expert panel, which outlined the following approach to dosing of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> in opioid-tolerant patients [<a href="#rid38">38</a>]:</p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving &lt;60 mg oral <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> per day or equivalent (OME), the initial <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dose should be no more than 7.5 mg oral methadone daily (eg, 2.5 mg three times daily).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving 60 to 199 mg OMEs and &lt;65 years of age, use a 10:1 conversion (ie, 10 mg OME:1 mg oral <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving ≥200 mg OME and/or patients &gt;65 years of age, use a 20:1 conversion (ie, 20 mg OME:1 mg oral <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>These and other guidelines also recommend converting to a <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dose no greater than 30 to 40 mg per day, regardless of the previous opioid dose [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dose should not be increased before five to seven days, and should not be increased by more than 5 mg/day up to 30 to 40 mg/day, and then can be increased by 10 mg/day (after five to seven days).</p><p></p><p>There are two dominant strategies for introducing <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>: the "stop and go" approach, where the current opioid is immediately replaced by methadone, and the three-day switch, where the dose of the current opioid is reduced step-wise by one-third each day, and substituted with one-third of the equianalgesic dose of methadone, over three days [<a href="#rid132">132-137</a>]. There is insufficient evidence to select one strategy preferentially over another [<a href="#rid138">138</a>]. The “stop and go” approach may increase the risk of poorly controlled pain, particularly when pain is severe. If there is concern about this, a PRN (q4h) rescue dose of a short-acting opioid (such as <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> at a dose equianalgesic to one-sixth of the prior total daily dose) may be added to the starting methadone dose. Switching over a three-day period is probably a preferable strategy as it may avoid methadone accumulation and toxicity, particularly in patients on high doses of opioids and will avoid major pain exacerbation caused by stopping all the current opioid before the methadone levels are adequate to provide sufficient analgesia [<a href="#rid10">10,12,139</a>].</p><p class="headingAnchor" id="H2039534146"><span class="h5">Switching from methadone</span><span class="headingEndMark"> — </span>There have been no studies of approaches to increase the safety and efficacy of rotation from <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> to another pure mu agonist opioid The switch must begin with the calculated equianalgesic dose of the new opioid.</p><p>Many clinicians use a 1:3 conversion rate from <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> to oral <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, as suggested by McPherson [<a href="#rid140">140</a>]. As an example, an individual receiving 7.5 mg of methadone twice daily would receive an initial dose of 45 mg (15 X 3) oral morphine per day.</p><p>The <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> is stopped concurrent with initiation of the new drug, but monitoring during the next few days is essential, given the relatively long half-life of methadone. As methadone levels decline, the initial dose of the new drug may require substantial up-titration.</p><p>In the absence of studies demonstrating the safety and efficacy of rotation from <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> to other opioids, we would urge caution when using this approach if the dose of methadone is relatively high (eg, above 60 to 80 mg per day) and suggest obtaining a consultation from a palliative care clinician or anesthesia pain specialist before attempting a transition. If none is available, we recommend calculating the anticipated total dose of the new opioid that will be needed and providing one-half of that dose as a fixed scheduled dose and the other one half on an "as needed" basis in the first 24 to 48 hours.</p><p class="headingAnchor" id="H399094939"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119531.html" rel="external">"Society guideline links: Palliative care"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115871.html" rel="external">"Society guideline links: Neuropathic pain"</a> and  <a class="medical medical_society_guidelines" href="/d/html/119434.html" rel="external">"Society guideline links: Cancer pain"</a>.)</p><p class="headingAnchor" id="H26635380"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16249.html" rel="external">"Patient education: Managing pain when you have cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of opioids</strong> – Opioids are widely used for treatment of cancer pain because of their safety, multiple routes of administration, ease of titration, reliability, and effectiveness for all types of pain (ie, somatic, visceral, and neuropathic).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of initial opioid</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The management of chronic cancer pain usually involves the long-term administration of pure mu receptor agonists. (See <a class="local">'Opioid drugs used in cancer pain management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The oral and transdermal routes are preferred for treatment of chronic cancer pain. (See <a class="local">'Selecting the route of administration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with moderate to severe pain, we would choose initial treatment with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a>, or transdermal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>. (See <a class="local">'Pure mu agonists commonly used for cancer pain'</a> above.)</p><p></p><p class="bulletIndent2">Other acceptable options are transdermal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> or a mixed-mechanism drug such as <a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">tramadol</a> or <a class="drug drug_general" data-topicid="9511" href="/d/drug information/9511.html" rel="external">tapentadol</a>. (See <a class="local">'Buprenorphine'</a> above and <a class="local">'Mixed-mechanism drugs: Tramadol and tapentadol'</a> above.)</p><p></p><p class="bulletIndent2">Because of genetic variation in metabolism of <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> and an inability to predict drug effects, we suggest not using codeine in this setting (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We also suggest not using <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">meperidine</a> because of toxicity concerns (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Pure mu agonists rarely used for cancer pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If a short-acting mu agonist is selected, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> has the longest history of use for the treatment of cancer pain and is usually considered the standard for comparison across opioid drug classes. However, other drugs in the same class are also options, and there is no evidence to suggest superior efficacy or tolerability for any one agent over another in most circumstances. However:</p><p></p><p class="bulletIndent2">In the setting of poor gastrointestinal tract absorption or dysphagia, and for patients in whom constipation has been or is expected to be difficult to manage, we suggest transdermal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> over an orally administered opioid (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Selecting the opioid'</a> above and <a class="local">'Selecting the route of administration'</a> above.)</p><p></p><p class="bulletIndent2">For patients with kidney impairment, we suggest <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> or <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> rather than <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients with kidney impairment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower initial starting doses for most opioids are warranted in patients with chronic liver disease, and clinicians should be cautious prescribing opioids at "regular" dosing intervals until patients have demonstrated the lack of toxicity at the chosen dosing interval. As the liver disease progresses, prolonged dosing intervals may be needed. (See <a class="local">'Patients with chronic liver disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Given the challenges inherent in the safe prescribing of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, the drug should not be administered, without assistance, by clinicians who are unfamiliar with its unique pharmacology. It is usually considered for a trial after treatment with one or more alternative pure mu agonist opioids has been ineffective. If the clinician is not clear about the procedures that should be followed to ensure the safe use of methadone (starting dose, monitoring, timing of dose escalation, etc), it is best to seek the help of a palliative care consultant before starting this therapy. (See <a class="local">'Methadone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Titration and switch to a long-acting formulation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following selection of a starting opioid dose, adjustment is almost always required. Continuous or frequently recurrent pain is most effectively managed with a fixed schedule, "around-the-clock" opioid regimen. Although the absolute dose of the opioid is inconsequential as long as the balance between analgesia and side effects remains acceptable for the patient, the need to titrate to relatively high doses should be accompanied by careful reassessment of the pain and drug effects. (See <a class="local">'Dose titration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If a patient is needing several doses of a short-acting opioid per day (or if a bedtime dose does not permit uninterrupted sleep through the night), a switch to a long-acting modified-release formulation can improve convenience and adherence  (<a class="graphic graphic_table graphicRef111207" href="/d/graphic/111207.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing breakthrough pain</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with breakthrough pain should be offered a short-acting supplemental opioid on an as needed basis in conjunction with a fixed scheduled long-acting drug. The rescue drug is typically a single entity oral formulation, such as immediate release <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, or <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a>. A typical dose chosen for rescue is 5 to 15 percent of the basal daily requirement of opioid. (See <a class="local">'Management of breakthrough pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Breakthrough pain may also be targeted with one of the newer rapid-onset, transmucosal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>. Due to cost and limited experience, the transmucosal drugs are generally considered only after a patient has demonstrated a poor response to an oral rescue dose. If this approach is chosen, the initial rescue dose should be one of the lowest commercially available doses and not based upon the basal daily opioid requirement.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with severe pain, rapid titration of the opioid dose may be achieved using intravenous dosing at short intervals. A technique for accomplishing this involves the use of a patient-controlled analgesia (PCA) pump to administer a continuous infusion of opioid by either the intravenous or subcutaneous route, plus intermittent bolus "rescue doses." The intravenous route has the fastest onset of action. (See <a class="local">'Subcutaneous and intravenous administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing refractory pain</strong> – Several options are available for patients who develop treatment-limiting side effects during opioid dose titration  (<a class="graphic graphic_table graphicRef75273" href="/d/graphic/75273.html" rel="external">table 11</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One approach, opioid rotation, may improve the balance between pain relief and side effects. (See <a class="local">'How to perform opioid rotation'</a> above.)</p><p></p><p class="bulletIndent2">When switching between opioids, equianalgesic dose tables  (<a class="graphic graphic_table graphicRef111207" href="/d/graphic/111207.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef111216" href="/d/graphic/111216.html" rel="external">table 9</a>) have been developed as a means for comparing potencies between opioids. However, application of the ratios in the equianalgesic dose table to the clinical setting is limited by incomplete cross-tolerance and other factors. Clinical guidelines have been developed that incorporate reductions in the calculated equianalgesic dose based upon specific patient characteristics; clinical judgment must be used to apply them  (<a class="graphic graphic_table graphicRef59062" href="/d/graphic/59062.html" rel="external">table 12</a>). (See <a class="local">'Equianalgesic opioid dose conversion'</a> above.)</p><p></p><p class="bulletIndent2">Conversion to and from <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> requires special care given the uncertainty as to the appropriate ratio to use in conversion from another pure mu agonist to methadone. Initially, when transitioning to methadone from an alternative opioid, we suggest that the calculated equianalgesic dose  (<a class="graphic graphic_table graphicRef111216" href="/d/graphic/111216.html" rel="external">table 9</a>) be reduced by 75 to 90 percent  (<a class="graphic graphic_table graphicRef59062" href="/d/graphic/59062.html" rel="external">table 12</a>) [<a href="#rid129">129</a>]. Regardless of the oral <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> equivalent dose, we would not initiate methadone at a dose higher than 30 mg/day. (See <a class="local">'Switching to methadone'</a> above and <a class="local">'Switching from methadone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another approach that could be considered in patients who have specific types of pain for which opioid therapy alone is frequently ineffective (eg, neuropathic pain) is the use of adjuvant analgesics in conjunction with opioid therapy. (See  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Patients with neuropathic pain'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">WHO analgesic pain ladder available online. www.who.int/cancer/palliative/painladder/en/ (Accessed on September 06, 2011).</li><li><a class="nounderline abstract_t">Quigley C. Opioids in people with cancer-related pain. BMJ Clin Evid 2008; 2008.</a></li><li><a class="nounderline abstract_t">Mercadante S, Tirelli W, David F, et al. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain 2010; 26:794.</a></li><li><a class="nounderline abstract_t">Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review. Palliat Med 2011; 25:471.</a></li><li><a class="nounderline abstract_t">Riley J, Branford R, Droney J, et al. Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial. J Pain Symptom Manage 2015; 49:161.</a></li><li><a class="nounderline abstract_t">Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids. Ann Oncol 2016; 27:1107.</a></li><li><a class="nounderline abstract_t">Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev 2016; 4:CD003868.</a></li><li><a class="nounderline abstract_t">Bao YJ, Hou W, Kong XY, et al. Hydromorphone for cancer pain. Cochrane Database Syst Rev 2016; 10:CD011108.</a></li><li><a class="nounderline abstract_t">Nicholson AB, Watson GR, Derry S, Wiffen PJ. Methadone for cancer pain. Cochrane Database Syst Rev 2017; 2:CD003971.</a></li><li class="breakAll">Sjögren P. Clinical implications of morphine metabolites. In: Topics in Palliative Care Vol 1, Portenoy RK, Bruera EB (Eds), Oxford University Press, New York 1997. p.163.</li><li><a class="nounderline abstract_t">Penson RT, Joel SP, Gloyne A, et al. Morphine analgesia in cancer pain: role of the glucuronides. J Opioid Manag 2005; 1:83.</a></li><li><a class="nounderline abstract_t">Quigley C, Joel S, Patel N, et al. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med 2003; 17:185.</a></li><li><a class="nounderline abstract_t">Penson RT, Joel SP, Bakhshi K, et al. Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 2000; 68:667.</a></li><li><a class="nounderline abstract_t">Sjøgren P, Thunedborg LP, Christrup L, et al. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand 1998; 42:1070.</a></li><li><a class="nounderline abstract_t">Schmidt-Hansen M, Bennett MI, Arnold S, et al. Oxycodone for cancer-related pain. Cochrane Database Syst Rev 2017; 8:CD003870.</a></li><li><a class="nounderline abstract_t">Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage 2003; 25:169.</a></li><li><a class="nounderline abstract_t">Li Y, Ma J, Lu G, et al. Hydromorphone for cancer pain. Cochrane Database Syst Rev 2021; 8:CD011108.</a></li><li><a class="nounderline abstract_t">Mayyas F, Fayers P, Kaasa S, Dale O. A systematic review of oxymorphone in the management of chronic pain. J Pain Symptom Manage 2010; 39:296.</a></li><li class="breakAll">Endo Press Releases. Available at: http://endo.com/news-events/press-releases?c=123046&amp;p=irol-newsArticle&amp;ID=2284981 (Accessed on July 11, 2017).</li><li class="breakAll">FDA requests removal of Opana ER for risks related to abuse. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm (Accessed on July 11, 2017).</li><li><a class="nounderline abstract_t">Baek SK, Shin HW, Choi YJ, et al. Noninterventional observational study using high-dose controlled-release oxycodone (CR oxycodone) for cancer pain management in outpatient clinics. Pain Med 2013; 14:1866.</a></li><li><a class="nounderline abstract_t">Abuse-Deterrent Opioid Formulations. JAMA 2015; 314:1744.</a></li><li><a class="nounderline abstract_t">Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 2009; 13:737.</a></li><li><a class="nounderline abstract_t">Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13:254.</a></li><li><a class="nounderline abstract_t">van Seventer R, Smit JM, Schipper RM, et al. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003; 19:457.</a></li><li><a class="nounderline abstract_t">Wong JO, Chiu GL, Tsao CJ, Chang CL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997; 35:25.</a></li><li><a class="nounderline abstract_t">Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care 2009; 25:172.</a></li><li><a class="nounderline abstract_t">Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008; 11:492.</a></li><li><a class="nounderline abstract_t">Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev 2013; :CD010270.</a></li><li class="breakAll">FDA Public Health Advisory. Risk of burns during MRI scans from transdermal drug patches with metallic backings. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm111313.htm (Accessed on January 03, 2012).</li><li><a class="nounderline abstract_t">Chiba T, Takahashi H, Tairabune T, et al. Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. Biol Pharm Bull 2020; 43:873.</a></li><li><a class="nounderline abstract_t">Bryson J, Tamber A, Seccareccia D, Zimmermann C. Methadone for treatment of cancer pain. Curr Oncol Rep 2006; 8:282.</a></li><li><a class="nounderline abstract_t">Leppert W. The role of methadone in cancer pain treatment--a review. Int J Clin Pract 2009; 63:1095.</a></li><li><a class="nounderline abstract_t">Salpeter SR, Buckley JS, Bruera E. The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med 2013; 16:616.</a></li><li><a class="nounderline abstract_t">Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22:185.</a></li><li><a class="nounderline abstract_t">Connolly I, Zaleon C, Montagnini M. Management of severe neuropathic cancer pain: an illustrative case and review. Am J Hosp Palliat Care 2013; 30:83.</a></li><li class="breakAll">Practical Pain Management 2015; 15(2): Practical guide to the safe use of methadone. Article available online at http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/practical-guide-safe-use-methadone (Accessed on October 21, 2015).</li><li><a class="nounderline abstract_t">McPherson ML, Walker KA, Davis MP, et al. Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper. J Pain Symptom Manage 2019; 57:635.</a></li><li><a class="nounderline abstract_t">Mammana G, Bertolino M, Bruera E, et al. First-line methadone for cancer pain: titration time analysis. Support Care Cancer 2021; 29:6335.</a></li><li><a class="nounderline abstract_t">Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 2014; 15:321.</a></li><li><a class="nounderline abstract_t">Cruciani RA. Methadone: to ECG or not to ECG...That is still the question. J Pain Symptom Manage 2008; 36:545.</a></li><li><a class="nounderline abstract_t">Reddy S, Hui D, El Osta B, et al. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med 2010; 13:33.</a></li><li><a class="nounderline abstract_t">Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387.</a></li><li><a class="nounderline abstract_t">Straube C, Derry S, Jackson KC, et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database Syst Rev 2014; :CD006601.</a></li><li><a class="nounderline abstract_t">Crush J, Levy N, Knaggs RD, Lobo DN. Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labelling opioids as weak or strong. Br J Anaesth 2022; 129:137.</a></li><li class="breakAll">NCCN guidelines available online at https://www.nccn.org/professionals/physician_gls/ (Accessed on December 02, 2021).</li><li><a class="nounderline abstract_t">Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13:e58.</a></li><li class="breakAll">WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. https://www.who.int/publications/i/item/9789241550390 (Accessed on October 10, 2022).</li><li><a class="nounderline abstract_t">Bandieri E, Romero M, Ripamonti CI, et al. Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. J Clin Oncol 2016; 34:436.</a></li><li><a class="nounderline abstract_t">Otton SV, Schadel M, Cheung SW, et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993; 54:463.</a></li><li><a class="nounderline abstract_t">de Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 2003; 23:420.</a></li><li><a class="nounderline abstract_t">Lötsch J, Rohrbacher M, Schmidt H, et al. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 2009; 144:119.</a></li><li><a class="nounderline abstract_t">Prommer EE. Tramadol: does it have a role in cancer pain management? J Opioid Manag 2005; 1:131.</a></li><li><a class="nounderline abstract_t">Rodriguez RF, Castillo JM, Castillo MP, et al. Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial. Clin J Pain 2008; 24:1.</a></li><li><a class="nounderline abstract_t">Wiffen PJ, Derry S, Naessens K, Bell RF. Oral tapentadol for cancer pain. Cochrane Database Syst Rev 2015; :CD011460.</a></li><li><a class="nounderline abstract_t">Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev 2017; 5:CD012508.</a></li><li><a class="nounderline abstract_t">Webster L, Gudin J, Raffa RB, et al. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Med 2020; 21:714.</a></li><li><a class="nounderline abstract_t">Yassen A, Olofsen E, Romberg R, et al. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 2007; 81:50.</a></li><li><a class="nounderline abstract_t">Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005; 94:825.</a></li><li><a class="nounderline abstract_t">Mercadante S, Porzio G, Ferrera P, et al. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther 2009; 31:2134.</a></li><li><a class="nounderline abstract_t">Apolone G, Corli O, Negri E, et al. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group. Clin J Pain 2009; 25:671.</a></li><li><a class="nounderline abstract_t">Poulain P, Denier W, Douma J, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage 2008; 36:117.</a></li><li><a class="nounderline abstract_t">Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2006; 20 Suppl 1:s25.</a></li><li><a class="nounderline abstract_t">Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003; 25:150.</a></li><li><a class="nounderline abstract_t">Sarhan T, Doghem M. A cmparison of two transdermal drug delivery systems; buprenorphine and fentanyl for chronic pain management. Eur J Pain 2009; 13:S199.</a></li><li><a class="nounderline abstract_t">Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in long-term control of chronic pain in cancer patients. Front Biosci 2007; 12:1291.</a></li><li><a class="nounderline abstract_t">Pergolizzi JV Jr, Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009; 25:1517.</a></li><li><a class="nounderline abstract_t">Davis MP, Pasternak G, Behm B. Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. Drugs 2018; 78:1211.</a></li><li><a class="nounderline abstract_t">Schmidt-Hansen M, Taubert M, Bromham N, et al. The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. BMJ Support Palliat Care 2016; 6:292.</a></li><li><a class="nounderline abstract_t">Melilli G, Samolsky Dekel BG, Frenquelli C, et al. Transdermal opioids for cancer pain control in patients with renal impairment. J Opioid Manag 2014; 10:85.</a></li><li><a class="nounderline abstract_t">Huang R, Jiang L, Cao Y, et al. Comparative Efficacy of Therapeutics for Chronic Cancer Pain: A Bayesian Network Meta-Analysis. J Clin Oncol 2019; 37:1742.</a></li><li><a class="nounderline abstract_t">Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003; 26:1026.</a></li><li><a class="nounderline abstract_t">Chan GL, Matzke GR. Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm 1987; 21:773.</a></li><li><a class="nounderline abstract_t">Launay-Vacher V, Karie S, Fau JB, et al. Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain 2005; 6:137.</a></li><li><a class="nounderline abstract_t">Sande TA, Laird BJ, Fallon MT. The use of opioids in cancer patients with renal impairment-a systematic review. Support Care Cancer 2017; 25:661.</a></li><li><a class="nounderline abstract_t">Kurita GP, Lundström S, Sjøgren P, et al. Renal function and symptoms/adverse effects in opioid-treated patients with cancer. Acta Anaesthesiol Scand 2015; 59:1049.</a></li><li><a class="nounderline abstract_t">Lee KA, Ganta N, Horton JR, Chai E. Evidence for Neurotoxicity Due to Morphine or Hydromorphone Use in Renal Impairment: A Systematic Review. J Palliat Med 2016; 19:1179.</a></li><li><a class="nounderline abstract_t">Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8:13.</a></li><li><a class="nounderline abstract_t">Kullgren J, Le V, Wheeler W. Incidence of hydromorphone-induced neuroexcitation in hospice patients. J Palliat Med 2013; 16:1205.</a></li><li><a class="nounderline abstract_t">Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001; 15:26.</a></li><li><a class="nounderline abstract_t">Paramanandam G, Prommer E, Schwenke DC. Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone. J Palliat Med 2011; 14:1029.</a></li><li><a class="nounderline abstract_t">Oliverio C, Malone N, Rosielle DA. Opoid use in liver failure #260. J Palliat Med 2012; 15:1389.</a></li><li><a class="nounderline abstract_t">Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81:129.</a></li><li><a class="nounderline abstract_t">Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004; 18:177.</a></li><li><a class="nounderline abstract_t">Azhar A, Kim YJ, Haider A, et al. Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain. Oncologist 2019; 24:125.</a></li><li class="breakAll">FDA Takes Further Steps to Confront Opioid Crisis Through Risk Evaluation and Mitigation Strategy Programs. Available at: https://www.fda.gov/news-events/press-announcements/fda-takes-further-steps-confront-opioid-crisis-through-risk-evaluation-and-mitigation-strategy (Accessed on January 04, 2021).</li><li><a class="nounderline abstract_t">Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol 2010; 21:1308.</a></li><li><a class="nounderline abstract_t">Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol 2011; 9:224.</a></li><li><a class="nounderline abstract_t">Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2012; 28:859.</a></li><li><a class="nounderline abstract_t">Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage 2013; 46:573.</a></li><li><a class="nounderline abstract_t">Portenoy RK, Burton AW, Gabrail N, et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010; 151:617.</a></li><li><a class="nounderline abstract_t">Webster LR, Slevin KA, Narayana A, et al. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med 2013; 14:1332.</a></li><li><a class="nounderline abstract_t">Kosugi T, Hamada S, Takigawa C, et al. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. J Pain Symptom Manage 2014; 47:990.</a></li><li><a class="nounderline abstract_t">Mercadante S, Adile C, Cuomo A, et al. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study. J Pain Symptom Manage 2015; 50:579.</a></li><li><a class="nounderline abstract_t">Zecca E, Brunelli C, Centurioni F, et al. Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial. J Clin Oncol 2017; 35:759.</a></li><li><a class="nounderline abstract_t">Vasisht N, Gever LN, Tagarro I, Finn AL. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig 2009; 29:647.</a></li><li><a class="nounderline abstract_t">Bohme K, Likar R. Efficacy and tolerability of a new opioid fomulation, buprenorphine transdermal therapeutic system (TDS) in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clin 2003; 15:193.</a></li><li><a class="nounderline abstract_t">Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004; 26:1808.</a></li><li><a class="nounderline abstract_t">Naing C, Aung K, Racloz V, Yeoh PN. Safety and efficacy of transdermal buprenorphine for the relief of cancer pain. J Cancer Res Clin Oncol 2013; 139:1963.</a></li><li><a class="nounderline abstract_t">Bruera E, Fainsinger R, Spachynski K, et al. Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 1995; 13:1520.</a></li><li><a class="nounderline abstract_t">Walsh D, Tropiano PS. Long-term rectal administration of high-dose sustained-release morphine tablets. Support Care Cancer 2002; 10:653.</a></li><li><a class="nounderline abstract_t">Wilkinson TJ, Robinson BA, Begg EJ, et al. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemother Pharmacol 1992; 31:251.</a></li><li><a class="nounderline abstract_t">Moolenaar F, Meijler WJ, Frijlink HW, et al. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain. Eur J Clin Pharmacol 2000; 56:219.</a></li><li><a class="nounderline abstract_t">Wilcock A, Jacob JK, Charlesworth S, et al. Drugs given by a syringe driver: a prospective multicentre survey of palliative care services in the UK. Palliat Med 2006; 20:661.</a></li><li><a class="nounderline abstract_t">McNeill JA, Sherwood GD, Starck PL. The hidden error of mismanaged pain: a systems approach. J Pain Symptom Manage 2004; 28:47.</a></li><li><a class="nounderline abstract_t">Radbruch L, Loick G, Schulzeck S, et al. Intravenous titration with morphine for severe cancer pain: report of 28 cases. Clin J Pain 1999; 15:173.</a></li><li><a class="nounderline abstract_t">Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94:2033.</a></li><li><a class="nounderline abstract_t">Nijland L, Schmidt P, Frosch M, et al. Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review. Support Care Cancer 2019; 27:33.</a></li><li><a class="nounderline abstract_t">Martin EJ, Roeland EJ, Sharp MB, et al. Patient-Controlled Analgesia for Cancer-Related Pain: Clinical Predictors of Patient Outcomes. J Natl Compr Canc Netw 2017; 15:595.</a></li><li><a class="nounderline abstract_t">Korkmazsky M, Ghandehari J, Sanchez A, et al. Feasibility study of rapid opioid rotation and titration. Pain Physician 2011; 14:71.</a></li><li><a class="nounderline abstract_t">Lin R, Lin S, Feng S, et al. Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial. J Natl Compr Canc Netw 2021; 19:1148.</a></li><li><a class="nounderline abstract_t">Sloan PA. Neuraxial pain relief for intractable cancer pain. Curr Pain Headache Rep 2007; 11:283.</a></li><li><a class="nounderline abstract_t">Myers J, Chan V, Jarvis V, Walker-Dilks C. Intraspinal techniques for pain management in cancer patients: a systematic review. Support Care Cancer 2010; 18:137.</a></li><li><a class="nounderline abstract_t">Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20:4040.</a></li><li class="breakAll">Fine P, Portenoy RK. Opioid analgesia. New York: McGraw Hill, 2004. http://www.stoppain.org/pcd/content/forpros/opioidbook.asp (Accessed on April 21, 2011).</li><li><a class="nounderline abstract_t">Jost L, Roila F, ESMO Guidelines Working Group. Management of cancer pain: ESMO clinical recommendations. Ann Oncol 2008; 19 Suppl 2:ii119.</a></li><li><a class="nounderline abstract_t">Krakowski I, Theobald S, Balp L, et al. Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002). Br J Cancer 2003; 89 Suppl 1:S67.</a></li><li><a class="nounderline abstract_t">Cormie PJ, Nairn M, Welsh J, Guideline Development Group. Control of pain in adults with cancer: summary of SIGN guidelines. BMJ 2008; 337:a2154.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/ (Accessed on May 18, 2020).</li><li><a class="nounderline abstract_t">Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009; 3:1.</a></li><li><a class="nounderline abstract_t">William L, Macleod R. Management of breakthrough pain in patients with cancer. Drugs 2008; 68:913.</a></li><li><a class="nounderline abstract_t">Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022; 71:1.</a></li><li><a class="nounderline abstract_t">Paice JA, Portenoy R, Lacchetti C, et al. Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34:3325.</a></li><li><a class="nounderline abstract_t">Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage 2001; 21:144.</a></li><li><a class="nounderline abstract_t">Sacks T, Weissman DE, Arnold RM. Opioid poorly responsive cancer pain #215. J Palliat Med 2013; 16:696.</a></li><li><a class="nounderline abstract_t">Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001; 21:338.</a></li><li><a class="nounderline abstract_t">Reddy A, Yennurajalingam S, Pulivarthi K, et al. Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist 2013; 18:212.</a></li><li><a class="nounderline abstract_t">Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009; 38:426.</a></li><li><a class="nounderline abstract_t">Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 2009; 38:418.</a></li><li><a class="nounderline abstract_t">Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002; 20:348.</a></li><li><a class="nounderline abstract_t">Chatham MS, Dodds Ashley ES, Svengsouk JS, Juba KM. Dose ratios between high dose oral morphine or equivalents and oral methadone. J Palliat Med 2013; 16:947.</a></li><li><a class="nounderline abstract_t">Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 1998; 82:1167.</a></li><li><a class="nounderline abstract_t">Ripamonti C, De Conno F, Groff L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998; 9:79.</a></li><li><a class="nounderline abstract_t">Benítez-Rosario MA, Salinas-Martín A, Aguirre-Jaime A, et al. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. J Pain Symptom Manage 2009; 37:1061.</a></li><li><a class="nounderline abstract_t">Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999; 17:3307.</a></li><li><a class="nounderline abstract_t">Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19:2898.</a></li><li><a class="nounderline abstract_t">Parsons HA, de la Cruz M, El Osta B, et al. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010; 116:520.</a></li><li><a class="nounderline abstract_t">McLean S, Twomey F. Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. J Pain Symptom Manage 2015; 50:248.</a></li><li><a class="nounderline abstract_t">Moksnes K, Dale O, Rosland JH, et al. How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial. Eur J Cancer 2011; 47:2463.</a></li><li class="breakAll">McPherson ML. Methadone: a complex and challenging analgesic, but it's worth it!. In: Demystifying opioid conversion calculators, 2nd ed, American Society of Health System Pharmacists, Bethesda 2018. p.180.</li></ol></div><div id="topicVersionRevision">Topic 2814 Version 94.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.who.int/cancer/palliative/painladder/en/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : WHO analgesic pain ladder available online. www.who.int/cancer/palliative/painladder/en/ (Accessed on September 06, 2011).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19445735" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Opioids in people with cancer-related pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20973155" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21708853" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The role of hydromorphone in cancer pain treatment: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24975432" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26940689" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27105021" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Oral morphine for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27727452" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hydromorphone for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28177515" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Methadone for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28177515" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Methadone for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17319252" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Morphine analgesia in cancer pain: role of the glucuronides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12701850" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11180027" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Randomized placebo-controlled trial of the activity of the morphine glucuronides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9809090" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28829910" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Oxycodone for cancer-related pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12590032" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A systematic review of hydromorphone in acute and chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34350974" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hydromorphone for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152592" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A systematic review of oxymorphone in the management of chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152592" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A systematic review of oxymorphone in the management of chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152592" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A systematic review of oxymorphone in the management of chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24010556" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Noninterventional observational study using high-dose controlled-release oxycodone (CR oxycodone) for cancer pain management in outpatient clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26505600" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Abuse-Deterrent Opioid Formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977159" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9185430" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14594516" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9212478" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19824278" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18363493" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24096644" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Transdermal fentanyl for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24096644" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Transdermal fentanyl for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32378563" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17254528" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Methadone for treatment of cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570126" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The role of methadone in cancer pain treatment--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23556990" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14701781" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504863" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Management of severe neuropathic cancer pain: an illustrative case and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504863" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Management of severe neuropathic cancer pain: an illustrative case and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30578934" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33880639" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : First-line methadone for cancer pain: titration time analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24685458" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440771" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Methadone: to ECG or not to ECG...That is still the question.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19824814" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153406" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : QTc interval screening in methadone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25234029" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Codeine, alone and with paracetamol (acetaminophen), for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35397880" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labelling opioids as weak or strong.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35397880" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labelling opioids as weak or strong.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22300860" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22300860" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26644526" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7693389" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12920424" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19395173" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17315416" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Tramadol: does it have a role in cancer pain management?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180628" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26403220" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Oral tapentadol for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28510996" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tramadol with or without paracetamol (acetaminophen) for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31917418" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185999" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15833777" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19922884" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19920716" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18411010" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16764218" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Transdermal buprenorphine in cancer pain and palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637117" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A cmparison of two transdermal drug delivery systems; buprenorphine and fentanyl for chronic pain management</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17127381" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Buprenorphine in long-term control of chronic pain in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19435402" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30051169" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26669324" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24715663" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Transdermal opioids for cancer pain control in patients with renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30939089" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Comparative Efficacy of Therapeutics for Chronic Cancer Pain: A Bayesian Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14585554" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3322755" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772907" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27744535" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The use of opioids in cancer patients with renal impairment-a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25943005" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Renal function and symptoms/adverse effects in opioid-treated patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27399959" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Evidence for Neurotoxicity Due to Morphine or Hydromorphone Use in Renal Impairment: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8695073" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23930920" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Incidence of hydromorphone-induced neuroexcitation in hospice patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11212464" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21823925" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23206153" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Opoid use in liver failure #260.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10353500" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Breakthrough pain: characteristics and impact in patients with cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198130" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30254187" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30254187" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940014" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22055892" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22480131" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23380337" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800358" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855816" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24099893" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26303188" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28113021" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19715381" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Efficacy and tolerability of a new opioid fomulation, buprenorphine transdermal therapeutic system (TDS) in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15639693" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23922192" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Safety and efficacy of transdermal buprenorphine for the relief of cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751901" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12436225" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Long-term rectal administration of high-dose sustained-release morphine tablets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1464164" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10952476" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060264" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Drugs given by a syringe driver: a prospective multicentre survey of palliative care services in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15223084" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The hidden error of mismanaged pain: a systems approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10524469" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Intravenous titration with morphine for severe cancer pain: report of 28 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932906" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30056529" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28476739" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Patient-Controlled Analgesia for Cancer-Related Pain: Clinical Predictors of Patient Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21267044" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Feasibility study of rapid opioid rotation and titration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34343968" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17686392" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Neuraxial pain relief for intractable cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19943068" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Intraspinal techniques for pain management in cancer patients: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351602" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351602" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456748" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Management of cancer pain: ESMO clinical recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915905" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18987038" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Control of pain in adults with cancer: summary of SIGN guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18987038" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Control of pain in adults with cancer: summary of SIGN guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365156" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Impact and management of breakthrough pain in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18457459" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Management of breakthrough pain in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36327391" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27458286" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11226765" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Opioid poorly-responsive cancer pain. Part 1: clinical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23614716" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Opioid poorly responsive cancer pain #215.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11312049" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23238913" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19735903" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Opioid rotation: the science and the limitations of the equianalgesic dose table.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19735902" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Establishing "best practices" for opioid rotation: conclusions of an expert panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773191" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Opioid rotation in the management of refractory cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23662952" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Dose ratios between high dose oral morphine or equivalents and oral methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9506365" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9541687" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171458" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506634" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Rapid switching from morphine to methadone in cancer patients with poor response to morphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11387363" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19924788" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Methadone initiation and rotation in the outpatient setting for patients with cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25896106" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21775131" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
